Compare TG Therapeutics Inc (TGTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: TG Therapeutics Inc and Western Alliance Bancorporation are close in size by market cap, and Western Alliance Bancorporation pays a 2.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WAL | |
|---|---|---|
Market Cap | $8.26B | $8.84B |
Sector | Health | Financials |
52-Week High | $59.06 | $96.08 |
52-Week Low | $26.39 | $66.70 |
Enterprise Value | $8.50B | — |
Dividend Yield | — | 2.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
